American CryoStem Corporation Announces Agreement With The Nanoranch Division Of UHV Technologies For Cancer Research Utilizing ATCELL™
EATONTOWN, N.J., June 18, 2014 (GLOBE NEWSWIRE) -- American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has entered into initial agreements with the nanoRANCH Division of UHV Technologies, Inc. ("nanoRANCH") for the development of methods for the delivery of therapeutics and drugs focused upon cancer treatments utilizing adipose derived adult stem cells. The Company will be working with Dan Dimitrijevich, PhD to create new treatment delivery methods utilizing a combination of nanoRANCH unique technology and CRYO's clinically processed ATCELLs™.
Help employers find you! Check out all the jobs and post your resume.